Titre :

Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis.

Auteur(s) :

Boucher, A. [Auteur]
Pradier, M. [Auteur]
Lafondesmurs, B. [Auteur]
Thill, P. [Auteur]
Patoz, P. [Auteur]
Blondiaux, N. [Auteur]
Joulie, D. [Auteur]
Hennart, Benjamin [Auteur]
IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
Robineau, Olivier [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Senneville, Eric [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Titre de la revue :

Infectious Diseases Now

Nom court de la revue :

Infect Dis Now

Numéro :

54

Pagination :

104835

Date de publication :

2024-02

ISSN :

2666-9919

Mot(s)-clé(s) en anglais :

Bone
Diabetes-related foot osteomyelitis
Dalbavancin
Treatment

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation. Patients and methods Between January 2019 and ...
Lire la suite >Objectives We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation. Patients and methods Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin. Results Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission. Conclusions In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille
Institut Pasteur de Lille

Collections :

• IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2024-01-05T22:02:01Z
2024-02-23T09:49:00Z